THE EFFICACY AND SAFETY OF KEVERPRAZAN (H008) IN THE TREATMENT OF DUODENAL ULCER: A MULTICENTERED, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL TRIAL IN CHINA

Niandi Tan  ¹     Xinpu Miao  ²     Aijun Liao  ³     Chengxia Liu  ⁴     Hao Wu  ⁵     Honghui Chen  ⁶     Fangfang Li  ⁷     Qinghong Guo  ⁸     Shengbao Li  ⁹     Yanping Tang  ¹⁰     Min Xia  ¹¹     Youli Liu  ¹²     Xing Li  ¹³     Huixin Chen  ¹⁴     Xiaowei Liu  ¹⁵     Yan Zhang  ¹⁶     Zhenyu Zhang  ¹⁷     Mei Su  ¹⁸     Minhu Chen  ¹⁸     Yinglian Xiao  ^18    
1 The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
² Hainan Central Hospital, Haikou, China
³ The First Hospital, University of South China, Hengyang, China
⁴ Binzhou Medical University Hospital, Binzhou, China
⁵ The Second Affiliated Hospital and Yuying Children’s hospital of WMH, Wenzhou, China
⁶ The Second Hospital, University of South China, Hengyang, China
⁷ Chenzhou First People’s Hospital, Chenzhou, China
⁸ The First Hospital of Lanzhou University, Lanzhou, China
⁹ Taihe Hospital, Shiyan, China
¹⁰ Tianjin Hospital of ITCWM Nankai Hospital, Tianjin, China
¹¹ Wuxi People’s Hospital, Wuxi, China
¹² The People’s Hospital of Xuancheng City, Xuancheng, China
¹³ JiangXi PingXiang People’s Hospital, Pingxiang, China
¹⁴ Huizhou Municipal Central Hospital, Huizhou, China
¹⁵ Xiangya Hospital Central South University, Changsha, China
¹⁶ Zigong Fourth People’s Hospital, Zigong, China
¹⁷ Nanjing First Hospital, Nanjing, China
¹⁸ Jiangsu Carephar Pharmaceutical Co., Ltd, Nanjing, China

Session
Oesophageal, gastric and duodenal disorders (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)